Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco

Harry Lampiris, MD, reviews the current and future co-formulations available for HIV patients, with an eye towards simplifying antiretroviral treatment regimens. He summarizes research studies on rilpivirine, elvitegravir, cobicistat, dolutegravir and the new tenofovir prodrug, TAF. Evidence from treatment switching studies is reviewed as well. Presentation Date: January 23, 2013

Dr. Lampiris is a Professor of Clinical Medicine in the Department of Medicine, Infectious Diseases Section, based at the San Francisco Veterans Affairs Medical Center (VAMC). He is the Associate Program Director of the UCSF Infectious Disease Fellowship Program and a clinical preceptor at the ID Clinic at VAMC and at the UCSF 360 Positive Care Practice.